Skip to content
Boca Raton City Online – Lifestyle
Author:
Santhera Pharmaceuticals Holding AG
AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy
March 9, 2026
Santhera Announces Proposed Inclusion and Reimbursement of AGAMREE® (Vamorolone) within Spain’s National Health System for the Treatment of Duchenne Muscular Dystrophy
March 8, 2026
Santhera Appoints Stifel as Corporate Finance Advisor
March 5, 2026
←
Previous Page
1
2